Economic Burden of Ischemic Stroke Care

Ischaemic stroke imposes a substantial and multifaceted economic burden on health systems, society and individual patients. Direct medical expenditures encompass acute hospitalisation, imaging, thrombolytic and endovascular interventions, post-acute rehabilitation and long-term nursing care. These costs dominate total expenditure, driven chiefly by length of stay, intensity of rehabilitation services and recurrent admissions. Indirect costs—stemming from productivity losses due to disability, premature mortality and the substantial contribution of informal carers—further magnify the societal impact, often representing up to one-fifth of the overall economic burden. Variations in cost profiles across regions reflect disparities in healthcare delivery models, reimbursement mechanisms and demographic factors such as age and stroke severity. Projection studies indicate that ageing populations and rising incidence rates will escalate global stroke-related expenditure over the coming decades, threatening the sustainability of conventional care pathways. Economic evaluations have increasingly informed policy by comparing cost-effectiveness of acute therapies, secondary prevention and models of integrated care. Interventions that reduce hospital length of stay, promote early supported discharge and enhance functional recovery may offset long-term care costs. Moreover, incorporating the value of informal caregiving into budgeting and reimbursement frameworks has emerged as critical for a comprehensive understanding of resource allocation. Addressing the economic challenges of ischaemic stroke demands coordinated strategies spanning prevention, acute management, rehabilitation and social support to achieve both clinical and fiscal sustainability.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Economic Burden of Ischemic Stroke Care publication trend

The graph below shows the total number of articles in economic burden of ischemic stroke care across all publications each year (not limited to Nature Index journals).

Technical terms

Direct costs: Expenditures for acute medical care, rehabilitation, medications and long-term services associated with ischaemic stroke treatment.

Indirect costs: Economic losses due to productivity decline, premature mortality and informal caregiving not captured by healthcare budgets.

Cost-of-illness (COI) study: An analytic approach quantifying the overall economic impact of a disease by aggregating direct and indirect costs.

Length of stay (LOS): The duration of hospital admission, a key driver of resource utilisation and in-hospital costs.

Informal care: Unpaid assistance provided by family members or friends, representing a significant portion of societal stroke costs.

References

1. Economic Burden of Stroke Disease: A Systematic Review. International Journal of Environmental Research and Public Health (2021).
2. The future incidence, prevalence and costs of stroke in the UK. Age and Ageing (2020).
3. A cost analysis of the first year after stroke - early triage and inpatient rehabilitation may reduce long term costs. Swiss Medical Weekly (2008).
4. Medical Service Utilization and Direct Medical Cost of Stroke in Urban China. International Journal of Health Policy and Management (2020).